Share on StockTwits

Johnson & Johnson (NYSE:JNJ)‘s stock had its “hold” rating reaffirmed by investment analysts at Jefferies Group in a note issued to investors on Monday. They currently have a $108.00 price objective on the stock, down from their previous price objective of $114.00. Jefferies Group’s price objective would indicate a potential upside of 6.85% from the company’s current price.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.31% during mid-day trading on Monday, hitting $101.39. 2,706,272 shares of the company’s stock traded hands. Johnson & Johnson has a 1-year low of $85.50 and a 1-year high of $106.74. The stock has a 50-day moving average of $103.2 and a 200-day moving average of $98.38. The company has a market cap of $285.9 billion and a P/E ratio of 18.69.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 15th. The company reported $1.66 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.54 by $0.12. The company had revenue of $19.50 billion for the quarter, compared to the consensus estimate of $18.86 billion. During the same quarter in the prior year, the company posted $1.48 earnings per share. The company’s quarterly revenue was up 9.1% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post $5.92 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 2.77%. The ex-dividend date of this dividend is Friday, August 22nd.

JNJ has been the subject of a number of other recent research reports. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, July 16th. They now have a $122.00 price target on the stock, up previously from $117.00. Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of Johnson & Johnson in a research note on Wednesday, July 16th. They now have a $107.00 price target on the stock, up previously from $102.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, July 16th. They now have a $108.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and an average target price of $98.00.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.